|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
MERCK SHARP & DOHME INTERNATIONAL
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Heart failure, congestive |
|
Hypertension, essential |
| |
|
|
SIDE EFFECTS:
|
|
acute generalized exanthematous pustulosis (AGEP) |
|
agranulocytosis |
|
anaphylactoid reactions |
|
angioedema |
|
aplastic anemia |
|
azotemia |
|
cholestasis |
|
cough |
|
dizziness |
|
fatigue |
|
glomerulonephritis |
|
hemolytic anemia |
|
hepatic failure |
|
hepatic necrosis |
|
hepatitis |
|
hyperkalemia |
|
hypotension |
|
jaundice |
|
maculopapular rash |
|
neutropenia |
|
orthostatic hypotension |
|
pancytopenia |
|
pneumonitis |
|
renal tubular necrosis |
|
sinus tachycardia |
|
syncope |
|
teratogenesis |
|
thrombocytopenia |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
aortic stenosis |
|
autoimmune disease |
|
black patients |
|
bone marrow suppression |
|
breast-feeding |
|
cardiomyopathy |
|
cerebrovascular disease |
|
children |
|
collagen-vascular disease |
|
coronary artery disease |
|
desensitization procedures |
|
dialysis |
|
elderly |
|
heart failure |
|
hepatic disease |
|
hyperkalemia |
|
hyponatremia |
|
hypotension |
|
hypovolemia |
|
immunosuppression |
|
infants |
|
low-density lipoprotein apheresis |
|
neonates |
|
pregnancy |
|
renal artery stenosis |
|
renal disease |
|
renal failure |
|
renal impairment |
|
|
ADULT DOSE:
|
|
Antihypertensive-Intravenous (over at least five minutes), 1.25 mg every six hours .
Note: An initial dose of 625 mcg (0.625 mg) should be used in patients who are sodium- and water-depleted as a result of prior diuretic therapy, patients continuing to receive diuretic therapy, or patients with renal failure (creatinine clearance less than or equal to 30 mL per minute). Such patients should be observed for one hour after this initial dose, to watch for excessive hypotension. If the clinical response is inadequate after one hour, the 625 mcg (0.625 mg) dose may be repeated, and therapy continued at a dose of 1.25 mg every six hours. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
Note: Use of products containing benzyl alcohol is not recommended in neonates. A fatal toxic syndrome consisting of metabolic acidosis, CNS depression, respiratory problems, renal failure, hypotension, and possibly seizures and intracranial hemorrhages has been associated with this use.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|